Bengaluru, March 10, 2025: Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC); compare to the active ingredient in MiraLAX®2 Powder for Solution, 17 grams of Bayer HealthCare LLC.
According to Nielsen® syndicated data for the latest 52 weeks’ period ending February 22, 2025, the MiraLAX® Powder for Solution, 17 grams (OTC) market3 achieved annual sales of approximately $555.7 million*.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.”
